Viridian Therapeutics, Inc. (VRDN)
19.44
+1.06
(+5.77%)
USD |
NASDAQ |
Oct 15, 10:52
Viridian Therapeutics Total Long Term Debt (Quarterly) : 242.16M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 242.16M |
| March 31, 2026 | 50.44M |
| December 31, 2025 | 49.94M |
| September 30, 2025 | 23.09M |
| June 30, 2025 | 22.49M |
| March 31, 2025 | 22.57M |
| December 31, 2024 | 22.58M |
| September 30, 2024 | 22.68M |
| June 30, 2024 | 22.05M |
| March 31, 2024 | 21.22M |
| December 31, 2023 | 21.20M |
| September 30, 2023 | 21.21M |
| June 30, 2023 | 6.13M |
| March 31, 2023 | 5.633M |
| December 31, 2022 | 5.745M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 5.523M |
| March 31, 2022 | 1.06M |
| December 31, 2021 | 0.52M |
| September 30, 2021 | 2.275M |
| June 30, 2021 | 1.167M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.043M |
| September 30, 2020 | 8.834M |
| June 30, 2020 | 8.797M |
| Date | Value |
|---|---|
| March 31, 2020 | 7.366M |
| December 31, 2019 | 8.304M |
| September 30, 2019 | 9.231M |
| June 30, 2019 | 10.15M |
| March 31, 2019 | 10.39M |
| December 31, 2018 | 10.30M |
| September 30, 2018 | 10.20M |
| June 30, 2018 | 10.11M |
| March 31, 2018 | 10.02M |
| December 31, 2017 | 9.922M |
| September 30, 2017 | 3.374M |
| June 30, 2017 | 3.85M |
| March 31, 2017 | 4.321M |
| December 31, 2016 | 4.789M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.08M |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.0106M |
| December 31, 2013 | 0.042M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 1.978B |
| TG Therapeutics, Inc. | 752.53M |
| Travere Therapeutics, Inc. | 610.74M |
| ACADIA Pharmaceuticals, Inc. | 59.55M |
| Alnylam Pharmaceuticals, Inc. | 2.942B |